Advertisement

PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas

  • Giuseppe Riva
  • Giancarlo Pecorari
  • Matteo Biolatti
  • Sara Pautasso
  • Irene Lo Cigno
  • Massimiliano Garzaro
  • Valentina Dell’Oste
  • Santo LandolfoEmail author
Original Article
  • 44 Downloads

Abstract

The aim of the present study is to determine the expression levels of PYHIN (IFI16 and AIM2) and APOBEC3 (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) gene family members in a cohort of patients with head and neck squamous cell carcinoma (HNSCC) and assess their potential correlation with human papillomavirus (HPV) infection status, clinical characteristics, and survival. For this purpose, 34 HNSCC tissue specimens along with healthy surrounding mucosa were collected from patients surgically treated for HNSCC. Nucleic acids were isolated to assess the presence of HPV and the expression levels of selected molecular markers. Survival analysis was carried out using the Kaplan–Meier method. In HPV-negative (HPV) HNSCCs, we detected low mRNA expression levels of IFI16, A3A, and A3B, whereas these genes were upregulated of 2–100 folds in HPV-positive (HPV+) tumors (p < 0.05). Interestingly, AIM2 gene expression levels were predominantly unchanged in HPV+ HNSCCs compared to their HPV counterparts, in which AIM2 was predominantly upregulated (10% vs. 50% of patients). In HPV tumors, upregulation of TP53, NOTCH1, PD-L1, and IFI16 correlated with lower occurrence of nodal metastases. On the other hand, the expression of APOBEC family members did not correlate with clinical characteristics. Regarding survival, patients with upregulated A3F gene expression had a worse prognosis, while patients without changes in A3H expression had a lower survival rate. In conclusion, our findings indicate that the innate immune sensors IFI16 and AIM2 and some APOBEC family members could be potentially used as biomarkers for disease outcome in HNSCC patients regardless of HPV presence.

Keywords

Head and neck cancer Human papillomavirus PYHIN proteins APOBEC proteins Survival 

Notes

Funding

This work was supported by: Italian Ministry of Education, University and Research-MIUR (PRIN 2015 to VDO, 2015RMNSTA); Research Funding from the University of Turin (DELV_RILO_17_01, LANS_RILO_17_01, 2018, to SL and VDO). The funding agencies had no role in study design, data collection and interpretation, as well as in the decision to submit this work for publication.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics. CA Cancer J Clin 55:74–108CrossRefGoogle Scholar
  2. 2.
    Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301.  https://doi.org/10.1200/JCO.2011.36.4596 CrossRefGoogle Scholar
  3. 3.
    Hoffmann TK, Sonkoly E, Hauser U et al (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44:1100–1109.  https://doi.org/10.1016/j.oraloncology.2008.02.006 CrossRefGoogle Scholar
  4. 4.
    Laskar S, Swain M (2015) HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it? J Cancer Res Ther 11:6.  https://doi.org/10.4103/0973-1482.151445 CrossRefGoogle Scholar
  5. 5.
    Colevas AD, Yom SS, Pfister DG et al (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Cancer Netw 16:479–490.  https://doi.org/10.6004/jnccn.2018.0026 CrossRefGoogle Scholar
  6. 6.
    Lampri ES, Chondrogiannis G, Ioachim E et al (2015) Biomarkers of head and neck cancer, tools or a gordian knot? Int J Clin Exp Med 8:10340–10357Google Scholar
  7. 7.
    Thariat J, Vignot S, Lapierre A et al (2015) Integrating genomics in head and neck cancer treatment: promises and pitfalls. Crit Rev Oncol Hematol 95:397–406.  https://doi.org/10.1016/j.critrevonc.2015.03.005 CrossRefGoogle Scholar
  8. 8.
    Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582.  https://doi.org/10.1038/nature14129 CrossRefGoogle Scholar
  9. 9.
    Goubau D, Rehwinkel J, e Sousa CR (2010) PYHIN proteins: center stage in DNA sensing. Nat Immunol 11:984–986.  https://doi.org/10.1038/ni1110-984 CrossRefGoogle Scholar
  10. 10.
    Mondini M, Costa S, Sponza S et al (2010) The interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication for autoimmunity. Autoimmunity 43:226–231.  https://doi.org/10.3109/08916930903510922 CrossRefGoogle Scholar
  11. 11.
    Mazibrada J, De Andrea M, Rittà M et al (2010) In vivo growth inhibition of head and neck squamous cell carcinoma by the Interferon-inducible gene IFI16. Cancer Lett 287:33–43.  https://doi.org/10.1016/j.canlet.2009.05.035 CrossRefGoogle Scholar
  12. 12.
    Unterholzner L, Keating SE, Baran M et al (2010) IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 11:997–1004.  https://doi.org/10.1038/ni.1932 CrossRefGoogle Scholar
  13. 13.
    Landolfo S, Gariglio M, Gribaudo G, Lembo D (1998) The Ifi 200 genes: an emerging family of IFN-inducible genes. Biochimie 80:721–728CrossRefGoogle Scholar
  14. 14.
    Dell’Oste V, Gatti D, Giorgio AG et al (2015) The interferon-inducible DNA-sensor protein IFI16: a key player in the antiviral response. New Microbiol 38:5–20Google Scholar
  15. 15.
    Man SM, Karki R, Kanneganti T-D (2016) AIM2 inflammasome in infection, cancer, and autoimmunity: role in DNA sensing, inflammation, and innate immunity. Eur J Immunol 46:269–280.  https://doi.org/10.1002/eji.201545839 CrossRefGoogle Scholar
  16. 16.
    Kuong KJ, Loeb LA (2013) APOBEC3B mutagenesis in cancer. Nat Genet 45:964–965.  https://doi.org/10.1038/ng.2736 CrossRefGoogle Scholar
  17. 17.
    Roberts SA, Lawrence MS, Klimczak LJ et al (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45:970–976.  https://doi.org/10.1038/ng.2702 CrossRefGoogle Scholar
  18. 18.
    Faden DL, Thomas S, Cantalupo PG et al (2017) Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. Oral Oncol 74:8–14.  https://doi.org/10.1016/j.oraloncology.2017.09.002 CrossRefGoogle Scholar
  19. 19.
    Conticello SG (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol 9:229.  https://doi.org/10.1186/gb-2008-9-6-229 CrossRefGoogle Scholar
  20. 20.
    Pautasso S, Galitska G, Dell’Oste V et al (2018) Evasion strategy of human cytomegalovirus to escape interferon-β-induced APOBEC3G editing activity. J Virol.  https://doi.org/10.1128/JVI.01224-18 Google Scholar
  21. 21.
    Ahasan MM, Wakae K, Wang Z et al (2015) APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity. Biochem Biophys Res Commun 457:295–299.  https://doi.org/10.1016/j.bbrc.2014.12.103 CrossRefGoogle Scholar
  22. 22.
    Lo Cigno I, De Andrea M, Borgogna C et al (2015) The nuclear DNA sensor IFI16 acts as a restriction factor for human papillomavirus replication through epigenetic modifications of the viral promoters. J Virol 89:7506–7520.  https://doi.org/10.1128/JVI.00013-15 CrossRefGoogle Scholar
  23. 23.
    Henderson S, Chakravarthy A, Su X et al (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833–1841.  https://doi.org/10.1016/j.celrep.2014.05.012 CrossRefGoogle Scholar
  24. 24.
    Fuessel Haws AL, He Q, Rady PL et al (2004) Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 122:87–93.  https://doi.org/10.1016/j.jviromet.2004.08.007 CrossRefGoogle Scholar
  25. 25.
    Rittà M, De Andrea M, Mondini M et al (2009) Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck.  https://doi.org/10.1002/hed.20977 Google Scholar
  26. 26.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.  https://doi.org/10.1006/meth.2001.1262 CrossRefGoogle Scholar
  27. 27.
    Rusz O, Pál M, Szilágyi É et al (2017) The expression of checkpoint and DNA repair genes in head and neck cancer as possible predictive factors. Pathol Oncol Res 23:253–264.  https://doi.org/10.1007/s12253-016-0088-z CrossRefGoogle Scholar
  28. 28.
    Shiboski CH, Schmidt BL, Jordan RCK (2005) Tongue and tonsil carcinoma. Cancer 103:1843–1849.  https://doi.org/10.1002/cncr.20998 CrossRefGoogle Scholar
  29. 29.
    Hammarstedt L, Lindquist D, Dahlstrand H et al (2006) Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119:2620–2623.  https://doi.org/10.1002/ijc.22177 CrossRefGoogle Scholar
  30. 30.
    Dyson N, Howley PM, Münger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937CrossRefGoogle Scholar
  31. 31.
    Scheffner M, Werness BA, Huibregtse JM et al (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136CrossRefGoogle Scholar
  32. 32.
    Westra WH, Taube JM, Poeta ML et al (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14:366–369.  https://doi.org/10.1158/1078-0432.CCR-07-1402 CrossRefGoogle Scholar
  33. 33.
    Weinberger PM, Yu Z, Haffty BG et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747.  https://doi.org/10.1200/JCO.2004.00.3335 CrossRefGoogle Scholar
  34. 34.
    Kumar B, Cordell KG, Lee JS et al (2008) EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128–3137.  https://doi.org/10.1200/JCO.2007.12.7662 CrossRefGoogle Scholar
  35. 35.
    Somers KD, Merrick MA, Lopez ME et al (1992) Frequent p53 mutations in head and neck cancer. Cancer Res 52:5997–6000Google Scholar
  36. 36.
    Alsner J, Sørensen SB, Overgaard J (2001) TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 59:179–185CrossRefGoogle Scholar
  37. 37.
    Kang H, Kiess A, Chung CH (2015) Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 12:11–26.  https://doi.org/10.1038/nrclinonc.2014.192 CrossRefGoogle Scholar
  38. 38.
    Yap LF, Lee D, Khairuddin A et al (2015) The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis 21:850–857.  https://doi.org/10.1111/odi.12309 CrossRefGoogle Scholar
  39. 39.
    Agrawal N, Frederick MJ, Pickering CR et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154–1157.  https://doi.org/10.1126/science.1206923 CrossRefGoogle Scholar
  40. 40.
    Ettl T, Viale-Bouroncle S, Hautmann MG et al (2015) AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines. Oral Oncol 51:158–163.  https://doi.org/10.1016/j.oraloncology.2014.11.005 CrossRefGoogle Scholar
  41. 41.
    Madoz-Gúrpide J, Zazo S, Chamizo C et al (2015) Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med 13:282.  https://doi.org/10.1186/s12967-015-0633-7 CrossRefGoogle Scholar
  42. 42.
    Flies DB, Sandler BJ, Sznol M, Chen L (2011) Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 84:409–421Google Scholar
  43. 43.
    Kim HS, Lee JY, Lim SH et al (2016) Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat 48:527–536.  https://doi.org/10.4143/crt.2015.249 CrossRefGoogle Scholar
  44. 44.
    Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532.  https://doi.org/10.1056/NEJMoa1503093 CrossRefGoogle Scholar
  45. 45.
    Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028.  https://doi.org/10.1056/NEJMoa1501824 CrossRefGoogle Scholar
  46. 46.
    Bauml J, Seiwert TY, Pfister DG et al (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35:1542–1549.  https://doi.org/10.1200/JCO.2016.70.1524 CrossRefGoogle Scholar
  47. 47.
    Mazibrada J, Longo L, Vatrano S et al (2014) Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis. New Microbiol 37:129–143Google Scholar
  48. 48.
    Kondo Y, Nagai K, Nakahata S et al (2012) Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci 103:782–790.  https://doi.org/10.1111/j.1349-7006.2012.02211.x CrossRefGoogle Scholar
  49. 49.
    Piccaluga PP, Agostinelli C, Fuligni F et al (2015) IFI16 expression Is related to selected transcription factors during B-Cell differentiation. J Immunol Res 2015:747645.  https://doi.org/10.1155/2015/747645 CrossRefGoogle Scholar
  50. 50.
    Kondo S, Wakae K, Wakisaka N et al (2017) APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene 36:1687–1697.  https://doi.org/10.1038/onc.2016.335 CrossRefGoogle Scholar
  51. 51.
    Chen T-W, Lee C-C, Liu H et al (2017) APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun 8:465.  https://doi.org/10.1038/s41467-017-00493-9 CrossRefGoogle Scholar
  52. 52.
    Gao J, Choudhry H, Cao W (2018) Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis. Cancer Sci 109:2375–2382.  https://doi.org/10.1111/cas.13658 CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Public Health and Pediatric SciencesUniversity of TurinTurinItaly
  2. 2.Otorhinolaryngology Division, Department of Surgical SciencesUniversity of TurinTurinItaly
  3. 3.Department of Translational MedicineUniversity of Eastern Piedmont “A. Avogadro”NovaraItaly
  4. 4.Otorhinolaryngology Division, Department of SurgeryUniversity of Eastern Piedmont “A. Avogadro”NovaraItaly

Personalised recommendations